Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-09-17

AUTHORS

Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan. More... »

PAGES

951-963

References to SciGraph publications

  • 2012-02-11. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study in JOURNAL OF GASTROENTEROLOGY
  • 2017-07-01. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials in JOURNAL OF GASTROENTEROLOGY
  • 2020-01-22. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects in SCIENTIFIC REPORTS
  • 2015-02-24. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in JOURNAL OF GASTROENTEROLOGY
  • 2012-01-27. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials in DIABETOLOGIA
  • 2018-05-09. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study in JOURNAL OF GASTROENTEROLOGY
  • 2011-10-18. Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • 2006-04. Reactive oxygen species have a causal role in multiple forms of insulin resistance in NATURE
  • 2012-02-01. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity in NATURE
  • 2011-07-13. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease in JOURNAL OF GASTROENTEROLOGY
  • 2012-01-05. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population in BMC GASTROENTEROLOGY
  • 2017-09-20. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention in NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
  • 2014-02-16. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease in NATURE GENETICS
  • 2017-07-03. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals in SCIENTIFIC REPORTS
  • 2008-09-25. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease in NATURE GENETICS
  • 2010-09-16. Prevalence, gender, ethnic variations, and prognosis of NASH in JOURNAL OF GASTROENTEROLOGY
  • 2015-01-22. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan in HEPATOLOGY INTERNATIONAL
  • 2016-10-11. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x

    DOI

    http://dx.doi.org/10.1007/s00535-021-01796-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1141192505

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34533632


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Progression", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Evidence-Based Practice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Guidelines as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Japan", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Non-alcoholic Fatty Liver Disease", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410818.4", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
                "Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tokushige", 
            "givenName": "Katsutoshi", 
            "id": "sg:person.01161346545.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161346545.50"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ikejima", 
            "givenName": "Kenichi", 
            "id": "sg:person.0607415435.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607415435.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ono", 
            "givenName": "Masafumi", 
            "id": "sg:person.01077500221.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077500221.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Eguchi", 
            "givenName": "Yuichiro", 
            "id": "sg:person.0617655144.72", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617655144.72"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kamada", 
            "givenName": "Yoshihiro", 
            "id": "sg:person.01052677526.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052677526.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Itoh", 
            "givenName": "Yoshito", 
            "id": "sg:person.01017130226.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017130226.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Akuta", 
            "givenName": "Norio", 
            "id": "sg:person.01111770263.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111770263.06"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yoneda", 
            "givenName": "Masato", 
            "id": "sg:person.011766317402.99", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011766317402.99"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Iwasa", 
            "givenName": "Motoh", 
            "id": "sg:person.01105625564.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105625564.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yoneda", 
            "givenName": "Masashi", 
            "id": "sg:person.013606074302.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013606074302.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Otsuka", 
            "givenName": "Motoyuki", 
            "id": "sg:person.01315063735.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315063735.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tamaki", 
            "givenName": "Nobuharu", 
            "id": "sg:person.0603023143.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603023143.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kogiso", 
            "givenName": "Tomomi", 
            "id": "sg:person.01173722134.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173722134.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Miwa", 
            "givenName": "Hiroto", 
            "id": "sg:person.0611747536.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611747536.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chayama", 
            "givenName": "Kazuaki", 
            "id": "sg:person.01277325545.79", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277325545.79"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Enomoto", 
            "givenName": "Nobuyuki", 
            "id": "sg:person.01353463070.60", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353463070.60"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shimosegawa", 
            "givenName": "Tooru", 
            "id": "sg:person.01255535707.76", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255535707.76"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Takehara", 
            "givenName": "Tetsuo", 
            "id": "sg:person.01207223634.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207223634.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Koike", 
            "givenName": "Kazuhiko", 
            "id": "sg:person.01231713652.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231713652.67"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nature04634", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030208897", 
              "https://doi.org/10.1038/nature04634"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrgastro.2017.109", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091858590", 
              "https://doi.org/10.1038/nrgastro.2017.109"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00535-015-1050-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032449418", 
              "https://doi.org/10.1007/s00535-015-1050-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-011-2446-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021177494", 
              "https://doi.org/10.1007/s00125-011-2446-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-230x-12-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028332469", 
              "https://doi.org/10.1186/1471-230x-12-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12072-014-9605-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008920821", 
              "https://doi.org/10.1007/s12072-014-9605-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature10809", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022220176", 
              "https://doi.org/10.1038/nature10809"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ajg.2011.327", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045853983", 
              "https://doi.org/10.1038/ajg.2011.327"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.257", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045345124", 
              "https://doi.org/10.1038/ng.257"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-017-04991-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1087302773", 
              "https://doi.org/10.1038/s41598-017-04991-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-020-57935-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1124223309", 
              "https://doi.org/10.1038/s41598-020-57935-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00535-017-1364-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090324716", 
              "https://doi.org/10.1007/s00535-017-1364-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.2901", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008453458", 
              "https://doi.org/10.1038/ng.2901"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00535-018-1474-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103901166", 
              "https://doi.org/10.1007/s00535-018-1474-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00535-010-0311-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038400215", 
              "https://doi.org/10.1007/s00535-010-0311-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00535-011-0436-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004332631", 
              "https://doi.org/10.1007/s00535-011-0436-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ajg.2016.453", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006298465", 
              "https://doi.org/10.1038/ajg.2016.453"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00535-012-0533-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009954415", 
              "https://doi.org/10.1007/s00535-012-0533-z"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-09-17", 
        "datePublishedReg": "2021-09-17", 
        "description": "Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00535-021-01796-x", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1009747", 
            "issn": [
              "0944-1174", 
              "1435-5922"
            ], 
            "name": "Journal of Gastroenterology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "56"
          }
        ], 
        "keywords": [
          "nonalcoholic fatty liver disease", 
          "NAFLD/nonalcoholic steatohepatitis", 
          "nonalcoholic steatohepatitis", 
          "clinical practice guidelines", 
          "NAFLD patients", 
          "hepatocellular carcinoma", 
          "hepatic fibrosis", 
          "liver disease", 
          "practice guidelines", 
          "evidence-based clinical practice guidelines", 
          "glucagon-like peptide-1 analog", 
          "surveillance of HCC", 
          "non-viral liver disease", 
          "cardiovascular disease events", 
          "fatty liver disease", 
          "important prognostic factor", 
          "serious public health issue", 
          "peptide-1 analog", 
          "specific drug therapy", 
          "public health issue", 
          "Recommendations Assessment", 
          "hepatocyte ballooning", 
          "NAFLD/", 
          "liver cirrhosis", 
          "prognostic factors", 
          "liver biopsy", 
          "sodium glucose", 
          "clinical evidence", 
          "drug therapy", 
          "current therapies", 
          "definite diagnosis", 
          "recent trials", 
          "effective therapy", 
          "drug trials", 
          "disease events", 
          "effective screening method", 
          "vitamin E", 
          "patients", 
          "fibrosis", 
          "progressive form", 
          "therapy", 
          "health issues", 
          "disease", 
          "thiazolidinedione derivatives", 
          "effective screening", 
          "Western countries", 
          "trials", 
          "guidelines", 
          "Japan Society", 
          "wide spectrum", 
          "background questions", 
          "screening method", 
          "Japanese Society", 
          "steatohepatitis", 
          "cirrhosis", 
          "biopsy", 
          "gastroenterologists", 
          "carcinoma", 
          "CVD", 
          "Hepatology", 
          "etiology", 
          "gastroenterology", 
          "diagnosis", 
          "ballooning", 
          "core essentials", 
          "risk", 
          "surveillance", 
          "inhibitors", 
          "glucose", 
          "screening", 
          "practical guidelines", 
          "grade", 
          "evidence", 
          "assessment", 
          "English summaries", 
          "close attention", 
          "factors", 
          "Japan", 
          "summary", 
          "events", 
          "presence", 
          "evaluation system", 
          "analogues", 
          "addition", 
          "development", 
          "essential", 
          "countries", 
          "method", 
          "conjunction", 
          "society", 
          "definition", 
          "questions", 
          "system", 
          "form", 
          "attention", 
          "derivatives", 
          "issues", 
          "concept", 
          "spectra"
        ], 
        "name": "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020", 
        "pagination": "951-963", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1141192505"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00535-021-01796-x"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34533632"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00535-021-01796-x", 
          "https://app.dimensions.ai/details/publication/pub.1141192505"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T17:11", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_895.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00535-021-01796-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    388 TRIPLES      21 PREDICATES      148 URIs      122 LITERALS      13 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00535-021-01796-x schema:about N0028e291e8d5485188888e9a2a798192
    2 N045e48c7e35b44b3b267e5b9515ab91a
    3 N50ee2edfc9094418861bec558495e569
    4 N7f52021d1289469f99c9112b5a23bde3
    5 N9f2e5cbe1a954bb9bbde8e6344dbfbc5
    6 Nea301d709cee4f99a9dd3724aa251d98
    7 anzsrc-for:11
    8 anzsrc-for:1102
    9 schema:author N94e0c939e285403fb05c85d82e04a317
    10 schema:citation sg:pub.10.1007/s00125-011-2446-4
    11 sg:pub.10.1007/s00535-010-0311-8
    12 sg:pub.10.1007/s00535-011-0436-4
    13 sg:pub.10.1007/s00535-012-0533-z
    14 sg:pub.10.1007/s00535-015-1050-7
    15 sg:pub.10.1007/s00535-017-1364-8
    16 sg:pub.10.1007/s00535-018-1474-y
    17 sg:pub.10.1007/s12072-014-9605-x
    18 sg:pub.10.1038/ajg.2011.327
    19 sg:pub.10.1038/ajg.2016.453
    20 sg:pub.10.1038/nature04634
    21 sg:pub.10.1038/nature10809
    22 sg:pub.10.1038/ng.257
    23 sg:pub.10.1038/ng.2901
    24 sg:pub.10.1038/nrgastro.2017.109
    25 sg:pub.10.1038/s41598-017-04991-0
    26 sg:pub.10.1038/s41598-020-57935-6
    27 sg:pub.10.1186/1471-230x-12-2
    28 schema:datePublished 2021-09-17
    29 schema:datePublishedReg 2021-09-17
    30 schema:description Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.
    31 schema:genre article
    32 schema:isAccessibleForFree true
    33 schema:isPartOf N65d274d25200439fbc6a9d4ea48082a4
    34 N702920b8e3ed4ac1a6aafb8c1a8fad96
    35 sg:journal.1009747
    36 schema:keywords CVD
    37 English summaries
    38 Hepatology
    39 Japan
    40 Japan Society
    41 Japanese Society
    42 NAFLD patients
    43 NAFLD/
    44 NAFLD/nonalcoholic steatohepatitis
    45 Recommendations Assessment
    46 Western countries
    47 addition
    48 analogues
    49 assessment
    50 attention
    51 background questions
    52 ballooning
    53 biopsy
    54 carcinoma
    55 cardiovascular disease events
    56 cirrhosis
    57 clinical evidence
    58 clinical practice guidelines
    59 close attention
    60 concept
    61 conjunction
    62 core essentials
    63 countries
    64 current therapies
    65 definite diagnosis
    66 definition
    67 derivatives
    68 development
    69 diagnosis
    70 disease
    71 disease events
    72 drug therapy
    73 drug trials
    74 effective screening
    75 effective screening method
    76 effective therapy
    77 essential
    78 etiology
    79 evaluation system
    80 events
    81 evidence
    82 evidence-based clinical practice guidelines
    83 factors
    84 fatty liver disease
    85 fibrosis
    86 form
    87 gastroenterologists
    88 gastroenterology
    89 glucagon-like peptide-1 analog
    90 glucose
    91 grade
    92 guidelines
    93 health issues
    94 hepatic fibrosis
    95 hepatocellular carcinoma
    96 hepatocyte ballooning
    97 important prognostic factor
    98 inhibitors
    99 issues
    100 liver biopsy
    101 liver cirrhosis
    102 liver disease
    103 method
    104 non-viral liver disease
    105 nonalcoholic fatty liver disease
    106 nonalcoholic steatohepatitis
    107 patients
    108 peptide-1 analog
    109 practical guidelines
    110 practice guidelines
    111 presence
    112 prognostic factors
    113 progressive form
    114 public health issue
    115 questions
    116 recent trials
    117 risk
    118 screening
    119 screening method
    120 serious public health issue
    121 society
    122 sodium glucose
    123 specific drug therapy
    124 spectra
    125 steatohepatitis
    126 summary
    127 surveillance
    128 surveillance of HCC
    129 system
    130 therapy
    131 thiazolidinedione derivatives
    132 trials
    133 vitamin E
    134 wide spectrum
    135 schema:name Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
    136 schema:pagination 951-963
    137 schema:productId N15cc97e9588e4e3cab840063b082677f
    138 N9de30ba867824c59b6b4e38a860f9d37
    139 Nf2857187adba4f24b9719cc9208870ce
    140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141192505
    141 https://doi.org/10.1007/s00535-021-01796-x
    142 schema:sdDatePublished 2022-08-04T17:11
    143 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    144 schema:sdPublisher N977cfa6e3cd640178144a4ce07cb753f
    145 schema:url https://doi.org/10.1007/s00535-021-01796-x
    146 sgo:license sg:explorer/license/
    147 sgo:sdDataset articles
    148 rdf:type schema:ScholarlyArticle
    149 N0028e291e8d5485188888e9a2a798192 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Disease Progression
    151 rdf:type schema:DefinedTerm
    152 N045e48c7e35b44b3b267e5b9515ab91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Japan
    154 rdf:type schema:DefinedTerm
    155 N130489af115f40ff82e4ac1ccecbde15 rdf:first sg:person.0617655144.72
    156 rdf:rest N3fa99f1d3c614bcfbfe0f02484910f6c
    157 N15cc97e9588e4e3cab840063b082677f schema:name doi
    158 schema:value 10.1007/s00535-021-01796-x
    159 rdf:type schema:PropertyValue
    160 N3fa99f1d3c614bcfbfe0f02484910f6c rdf:first sg:person.01052677526.47
    161 rdf:rest Nd06beb78de1043869ac007a76d9329f7
    162 N50ee2edfc9094418861bec558495e569 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Humans
    164 rdf:type schema:DefinedTerm
    165 N5486362125a0493eb854c4c183fbe023 rdf:first sg:person.01111770263.06
    166 rdf:rest N82c3db5f5c63488ba5441378048ff162
    167 N5ae7d919ad07413d8d8e63cc122ecea5 rdf:first sg:person.013606074302.33
    168 rdf:rest N85fa6e27535c49dc8edf31102ecf59e6
    169 N65d274d25200439fbc6a9d4ea48082a4 schema:volumeNumber 56
    170 rdf:type schema:PublicationVolume
    171 N702920b8e3ed4ac1a6aafb8c1a8fad96 schema:issueNumber 11
    172 rdf:type schema:PublicationIssue
    173 N7692b6b1b23b4f4e97c4635500d9460f rdf:first sg:person.01173722134.47
    174 rdf:rest Nf2fb63ae4d2143bca351cefb74cd187a
    175 N7d17f0f6b1a24b6a820ba65003010489 rdf:first sg:person.01277325545.79
    176 rdf:rest Nf1904c776f964dee8dc52dd56631f0ea
    177 N7f52021d1289469f99c9112b5a23bde3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Evidence-Based Practice
    179 rdf:type schema:DefinedTerm
    180 N82c3db5f5c63488ba5441378048ff162 rdf:first sg:person.011766317402.99
    181 rdf:rest N9100fd74e44e4ed7bcd2fb4bf57b5121
    182 N83d05352c0a940ca9471139a66856a8b rdf:first sg:person.01077500221.35
    183 rdf:rest N130489af115f40ff82e4ac1ccecbde15
    184 N85fa6e27535c49dc8edf31102ecf59e6 rdf:first sg:person.01315063735.13
    185 rdf:rest Na102ae52f21548ee84adaa9fd1486264
    186 N9100fd74e44e4ed7bcd2fb4bf57b5121 rdf:first sg:person.01105625564.62
    187 rdf:rest N5ae7d919ad07413d8d8e63cc122ecea5
    188 N94e0c939e285403fb05c85d82e04a317 rdf:first sg:person.01161346545.50
    189 rdf:rest Nc19e7bfc3146483aa790f55726856ec2
    190 N977cfa6e3cd640178144a4ce07cb753f schema:name Springer Nature - SN SciGraph project
    191 rdf:type schema:Organization
    192 N9de30ba867824c59b6b4e38a860f9d37 schema:name pubmed_id
    193 schema:value 34533632
    194 rdf:type schema:PropertyValue
    195 N9f2e5cbe1a954bb9bbde8e6344dbfbc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Non-alcoholic Fatty Liver Disease
    197 rdf:type schema:DefinedTerm
    198 Na102ae52f21548ee84adaa9fd1486264 rdf:first sg:person.0603023143.36
    199 rdf:rest N7692b6b1b23b4f4e97c4635500d9460f
    200 Naa2e909c1c5546679412b59ede966cf7 rdf:first sg:person.01207223634.98
    201 rdf:rest Nc0958cfb1b064307ab5c4232c636cb2b
    202 Nc0958cfb1b064307ab5c4232c636cb2b rdf:first sg:person.01231713652.67
    203 rdf:rest rdf:nil
    204 Nc19e7bfc3146483aa790f55726856ec2 rdf:first sg:person.0607415435.38
    205 rdf:rest N83d05352c0a940ca9471139a66856a8b
    206 Nd06beb78de1043869ac007a76d9329f7 rdf:first sg:person.01017130226.32
    207 rdf:rest N5486362125a0493eb854c4c183fbe023
    208 Nea301d709cee4f99a9dd3724aa251d98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Guidelines as Topic
    210 rdf:type schema:DefinedTerm
    211 Nf1904c776f964dee8dc52dd56631f0ea rdf:first sg:person.01353463070.60
    212 rdf:rest Nf20541c33f064791bc499d8b655446ca
    213 Nf20541c33f064791bc499d8b655446ca rdf:first sg:person.01255535707.76
    214 rdf:rest Naa2e909c1c5546679412b59ede966cf7
    215 Nf2857187adba4f24b9719cc9208870ce schema:name dimensions_id
    216 schema:value pub.1141192505
    217 rdf:type schema:PropertyValue
    218 Nf2fb63ae4d2143bca351cefb74cd187a rdf:first sg:person.0611747536.16
    219 rdf:rest N7d17f0f6b1a24b6a820ba65003010489
    220 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    221 schema:name Medical and Health Sciences
    222 rdf:type schema:DefinedTerm
    223 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    224 schema:name Cardiorespiratory Medicine and Haematology
    225 rdf:type schema:DefinedTerm
    226 sg:journal.1009747 schema:issn 0944-1174
    227 1435-5922
    228 schema:name Journal of Gastroenterology
    229 schema:publisher Springer Nature
    230 rdf:type schema:Periodical
    231 sg:person.01017130226.32 schema:affiliation grid-institutes:None
    232 schema:familyName Itoh
    233 schema:givenName Yoshito
    234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017130226.32
    235 rdf:type schema:Person
    236 sg:person.01052677526.47 schema:affiliation grid-institutes:None
    237 schema:familyName Kamada
    238 schema:givenName Yoshihiro
    239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052677526.47
    240 rdf:type schema:Person
    241 sg:person.01077500221.35 schema:affiliation grid-institutes:None
    242 schema:familyName Ono
    243 schema:givenName Masafumi
    244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077500221.35
    245 rdf:type schema:Person
    246 sg:person.01105625564.62 schema:affiliation grid-institutes:None
    247 schema:familyName Iwasa
    248 schema:givenName Motoh
    249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105625564.62
    250 rdf:type schema:Person
    251 sg:person.01111770263.06 schema:affiliation grid-institutes:None
    252 schema:familyName Akuta
    253 schema:givenName Norio
    254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111770263.06
    255 rdf:type schema:Person
    256 sg:person.01161346545.50 schema:affiliation grid-institutes:grid.410818.4
    257 schema:familyName Tokushige
    258 schema:givenName Katsutoshi
    259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161346545.50
    260 rdf:type schema:Person
    261 sg:person.01173722134.47 schema:affiliation grid-institutes:None
    262 schema:familyName Kogiso
    263 schema:givenName Tomomi
    264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173722134.47
    265 rdf:type schema:Person
    266 sg:person.011766317402.99 schema:affiliation grid-institutes:None
    267 schema:familyName Yoneda
    268 schema:givenName Masato
    269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011766317402.99
    270 rdf:type schema:Person
    271 sg:person.01207223634.98 schema:affiliation grid-institutes:None
    272 schema:familyName Takehara
    273 schema:givenName Tetsuo
    274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207223634.98
    275 rdf:type schema:Person
    276 sg:person.01231713652.67 schema:affiliation grid-institutes:None
    277 schema:familyName Koike
    278 schema:givenName Kazuhiko
    279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231713652.67
    280 rdf:type schema:Person
    281 sg:person.01255535707.76 schema:affiliation grid-institutes:None
    282 schema:familyName Shimosegawa
    283 schema:givenName Tooru
    284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255535707.76
    285 rdf:type schema:Person
    286 sg:person.01277325545.79 schema:affiliation grid-institutes:None
    287 schema:familyName Chayama
    288 schema:givenName Kazuaki
    289 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277325545.79
    290 rdf:type schema:Person
    291 sg:person.01315063735.13 schema:affiliation grid-institutes:None
    292 schema:familyName Otsuka
    293 schema:givenName Motoyuki
    294 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315063735.13
    295 rdf:type schema:Person
    296 sg:person.01353463070.60 schema:affiliation grid-institutes:None
    297 schema:familyName Enomoto
    298 schema:givenName Nobuyuki
    299 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353463070.60
    300 rdf:type schema:Person
    301 sg:person.013606074302.33 schema:affiliation grid-institutes:None
    302 schema:familyName Yoneda
    303 schema:givenName Masashi
    304 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013606074302.33
    305 rdf:type schema:Person
    306 sg:person.0603023143.36 schema:affiliation grid-institutes:None
    307 schema:familyName Tamaki
    308 schema:givenName Nobuharu
    309 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603023143.36
    310 rdf:type schema:Person
    311 sg:person.0607415435.38 schema:affiliation grid-institutes:None
    312 schema:familyName Ikejima
    313 schema:givenName Kenichi
    314 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607415435.38
    315 rdf:type schema:Person
    316 sg:person.0611747536.16 schema:affiliation grid-institutes:None
    317 schema:familyName Miwa
    318 schema:givenName Hiroto
    319 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611747536.16
    320 rdf:type schema:Person
    321 sg:person.0617655144.72 schema:affiliation grid-institutes:None
    322 schema:familyName Eguchi
    323 schema:givenName Yuichiro
    324 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617655144.72
    325 rdf:type schema:Person
    326 sg:pub.10.1007/s00125-011-2446-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021177494
    327 https://doi.org/10.1007/s00125-011-2446-4
    328 rdf:type schema:CreativeWork
    329 sg:pub.10.1007/s00535-010-0311-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038400215
    330 https://doi.org/10.1007/s00535-010-0311-8
    331 rdf:type schema:CreativeWork
    332 sg:pub.10.1007/s00535-011-0436-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004332631
    333 https://doi.org/10.1007/s00535-011-0436-4
    334 rdf:type schema:CreativeWork
    335 sg:pub.10.1007/s00535-012-0533-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1009954415
    336 https://doi.org/10.1007/s00535-012-0533-z
    337 rdf:type schema:CreativeWork
    338 sg:pub.10.1007/s00535-015-1050-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032449418
    339 https://doi.org/10.1007/s00535-015-1050-7
    340 rdf:type schema:CreativeWork
    341 sg:pub.10.1007/s00535-017-1364-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090324716
    342 https://doi.org/10.1007/s00535-017-1364-8
    343 rdf:type schema:CreativeWork
    344 sg:pub.10.1007/s00535-018-1474-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1103901166
    345 https://doi.org/10.1007/s00535-018-1474-y
    346 rdf:type schema:CreativeWork
    347 sg:pub.10.1007/s12072-014-9605-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008920821
    348 https://doi.org/10.1007/s12072-014-9605-x
    349 rdf:type schema:CreativeWork
    350 sg:pub.10.1038/ajg.2011.327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045853983
    351 https://doi.org/10.1038/ajg.2011.327
    352 rdf:type schema:CreativeWork
    353 sg:pub.10.1038/ajg.2016.453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006298465
    354 https://doi.org/10.1038/ajg.2016.453
    355 rdf:type schema:CreativeWork
    356 sg:pub.10.1038/nature04634 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030208897
    357 https://doi.org/10.1038/nature04634
    358 rdf:type schema:CreativeWork
    359 sg:pub.10.1038/nature10809 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022220176
    360 https://doi.org/10.1038/nature10809
    361 rdf:type schema:CreativeWork
    362 sg:pub.10.1038/ng.257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045345124
    363 https://doi.org/10.1038/ng.257
    364 rdf:type schema:CreativeWork
    365 sg:pub.10.1038/ng.2901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008453458
    366 https://doi.org/10.1038/ng.2901
    367 rdf:type schema:CreativeWork
    368 sg:pub.10.1038/nrgastro.2017.109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091858590
    369 https://doi.org/10.1038/nrgastro.2017.109
    370 rdf:type schema:CreativeWork
    371 sg:pub.10.1038/s41598-017-04991-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1087302773
    372 https://doi.org/10.1038/s41598-017-04991-0
    373 rdf:type schema:CreativeWork
    374 sg:pub.10.1038/s41598-020-57935-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124223309
    375 https://doi.org/10.1038/s41598-020-57935-6
    376 rdf:type schema:CreativeWork
    377 sg:pub.10.1186/1471-230x-12-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028332469
    378 https://doi.org/10.1186/1471-230x-12-2
    379 rdf:type schema:CreativeWork
    380 grid-institutes:None schema:alternateName Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan
    381 The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan
    382 schema:name Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan
    383 The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan
    384 rdf:type schema:Organization
    385 grid-institutes:grid.410818.4 schema:alternateName Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
    386 schema:name Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis’’, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan
    387 Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan
    388 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...